Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIME-NSCLC
NCT06882174Phase 2Not yet recruiting
- Sponsor
- American Health Staffing Group
- Start
- May 2026
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by American Health Staffing Group. Planned start May 2026; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06882174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06882174.